로딩 중…
지수 로딩 중…
이엔셀
456070· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩6,700+29.59%
2026-09-18
Financials
Valuation Metrics
이엔셀's Market Cap is ₩739B. At end of 2025 it was ₩2005B. Ranked #1494 of 2,421 in KR market (top 62%), #868 of 1,640 on KOSDAQ (top 53%), #161 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.90B KRW | KR#1,494/2,421 Sec#161/231 |
| Revenue | 4.16B KRW | KR#2,351/2,421 Sec#201/231 |
| Net Income | -19.62B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 55.08B KRW | KR#2,161/2,421 Sec#190/231 |
| Net Assets | 27.86B KRW | KR#2,200/2,421 Sec#200/231 |
| Employees | 112 | KR#1,557/2,421 Sec#121/231 |
| Value | ||
| P/B | 2.65x | KR#2,064/2,421 Sec#160/231 |
| P/S | 17.75x | KR#2,330/2,421 Sec#181/231 |
| FCF Yield | -18.05% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -70.43% | KR#2,322/2,421 Sec#210/231 |
| ROA | -35.62% | KR#2,335/2,421 Sec#206/231 |
| Op. Margin | -437.31% | KR#2,363/2,421 Sec#203/231 |
| Revenue Growth | -27.06% | KR#2,200/2,421 Sec#196/231 |
| Financial Health | ||
| Debt Ratio | 97.73% | KR#1,538/2,421 Sec#175/231 |
| Total Debt | 9.77B KRW | KR#1,638/2,421 Sec#147/231 |
| FCF | -13.34B KRW | KR#1,793/2,421 Sec#160/231 |
| Cash | 21.40B KRW | KR#1,211/2,421 Sec#85/231 |
| Current Ratio | 7.06x | KR#172/2,421 Sec#38/231 |
| Performance | ||
| 1Y Return | -41.12% | KR#1,864/2,421 Sec#158/231 |
| 1M Return | 12.98% | KR#381/2,421 Sec#24/231 |
| From 52W High | -68.02% | KR#2,147/2,421 Sec#181/231 |
| 1Y MDD | -75.66% | KR#2,199/2,421 Sec#195/231 |
| Trading | ||
| Volume | 2,652,180 shares | KR#52/2,421 Sec#4/231 |
| Trading Value | 17.45B KRW | KR#183/2,421 Sec#11/231 |
| Foreign Own. | 3.96% | KR#1,057/2,421 Sec#94/231 |
| Per Share | ||
| EPS | -1,779 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,526 KRW | KR#1,950/2,421 Sec#154/231 |
Company Info
Based in Seoul, South Korea, Encell Co. Ltd., established in February 2018, focuses on the research, development, and manufacturing of biopharmaceuticals. The company offers tailored pharmaceutical development services, guiding projects from their initial concept through to regulatory approval.